Reno, Nevada 89502


This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.


Inclusion Criteria: - Male or female aged 18 years or older - Type 1 or type 2 Diabetes Mellitus - Central-involved DME with central subfield thickness of ≥ 320µm on Spectralis® spectral domain optical coherence tomography (SD-OCT) or ≥ 305µm on non-Spectralis SD-OCT, in the study eye - Best-corrected visual acuity (BCVA) ≤ 62 and ≥ 23 ETDRS letter score in the study eye - Written informed consent obtained from the subject prior to screening procedures Exclusion Criteria: - Macular edema due to causes other than DME - Concurrent disease in the study eye, other than central-involved DME, that could compromise BCVA, require medical or surgical intervention during the study period or could confound interpretation of the results - Any condition that could confound the ability to detect a change in central subfield thickness in the study eye - Previous confounding treatments / procedures, or expected to require confounding treatments / procedures at any time during the study period - Presence of neovascularization at the disc (NVD) in the study eye - Uncontrolled glaucoma in the study eye - Any active ocular / intra-ocular infection or inflammation in either eye - Poorly controlled Diabetes Mellitus - Uncontrolled hypertension



Primary Contact:

Study Director
Clinical Department
ThromboGenics Inc. A subsidiary of Oxurion NV.

Global Clinical Development
Phone: +32 (0)16 751 310

Backup Contact:


Location Contact:

Reno, Nevada 89502
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.